Glutaminase inhibitors inhibit pyrimidine synthesis and increase the ROS level in VHL-deficient RCC cells, and the PARP inhibitor olaparib and glutaminase inhibitors synergically inhibit the growth of these cells in vivo and in vitro (58). The gene discussed is GLS; the disease is renal cell carcinoma.